Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-384-250"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-384-250"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-384-5002
lpv:speaker	lp:Agnès Le Brun2
lpv:spokenAs	substitute; Delegation for relations with Switzerland and Norway and to the EU-Iceland Joint Parliamentary Committee and the European Economic Area (EEA) Joint Parliamentary Committee (2011-02-08--2014-06-30)3 unknown; Union pour un Mouvement Populaire (2011-01-01--2014-06-30)3 substitute; CONT (2012-01-19--2014-06-30)3 substitute; AFET (2012-01-19--2014-06-30)3 member; AGRI (2012-01-19--2014-06-30)3 vice-chair; DROI (2012-01-25--2012-10-21)3 member; EPP (2011-01-01--2014-06-30)3 member; Delegation for relations with Japan (2011-02-14--2014-06-30)3
lpv:translated text	"The marketing of products that are hazardous to health in Europe, such as Distilbène, Isoméride and Mediator, and the scandal that this has caused, have made Europe’s governments aware of the need to amend the current legislation. I voted in favour of this report because I think there is an urgent need for a new mechanism to deal with the system’s shortcomings. This mechanism will produce three key changes, namely: urgent assessment when a company decides not to renew a marketing licence, then the obligation to make a declaration when a company decides not to renew a marketing licence and, finally, the creation of an information panel for consumers on the packaging of medicines that have undergone a post-authorisation safety study."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph